Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 12 studies | 26% ± 7% | |
type I pneumocyte | 10 studies | 23% ± 8% | |
oligodendrocyte | 10 studies | 21% ± 7% | |
astrocyte | 4 studies | 31% ± 10% | |
glutamatergic neuron | 4 studies | 29% ± 10% | |
oligodendrocyte precursor cell | 4 studies | 26% ± 4% | |
epithelial cell | 3 studies | 22% ± 4% | |
hepatocyte | 3 studies | 50% ± 24% | |
GABAergic neuron | 3 studies | 28% ± 7% | |
interneuron | 3 studies | 30% ± 14% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 5 studies | 29% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 9062.32 | 459 / 459 | 100% | 72.18 | 1116 / 1118 |
skin | 100% | 12521.13 | 1809 / 1809 | 100% | 67.11 | 470 / 472 |
brain | 100% | 7099.20 | 2639 / 2642 | 100% | 78.04 | 702 / 705 |
esophagus | 100% | 9287.79 | 1445 / 1445 | 99% | 50.85 | 182 / 183 |
prostate | 100% | 5989.27 | 245 / 245 | 99% | 42.62 | 498 / 502 |
liver | 100% | 8833.01 | 226 / 226 | 98% | 38.69 | 398 / 406 |
lung | 100% | 10824.10 | 578 / 578 | 97% | 35.62 | 1124 / 1155 |
kidney | 100% | 4524.54 | 89 / 89 | 97% | 47.64 | 874 / 901 |
uterus | 100% | 6246.36 | 170 / 170 | 97% | 36.99 | 445 / 459 |
stomach | 100% | 4973.64 | 359 / 359 | 97% | 29.53 | 277 / 286 |
pancreas | 99% | 5439.81 | 325 / 328 | 98% | 34.26 | 174 / 178 |
ovary | 100% | 8598.08 | 180 / 180 | 96% | 35.82 | 411 / 430 |
thymus | 100% | 9223.27 | 653 / 653 | 95% | 51.09 | 577 / 605 |
intestine | 100% | 6209.14 | 966 / 966 | 95% | 25.18 | 501 / 527 |
adrenal gland | 100% | 8493.83 | 258 / 258 | 95% | 29.28 | 218 / 230 |
bladder | 100% | 5341.67 | 21 / 21 | 91% | 26.32 | 457 / 504 |
adipose | 100% | 7559.44 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 41.11 | 80 / 80 |
spleen | 100% | 15795.89 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 6201.01 | 1334 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 47.54 | 44 / 45 |
heart | 98% | 5255.68 | 841 / 861 | 0% | 0 | 0 / 0 |
muscle | 97% | 2921.53 | 777 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 79% | 3051.90 | 736 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 72% | 12.21 | 21 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0015014 | Biological process | heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process |
GO_0035904 | Biological process | aorta development |
GO_0006954 | Biological process | inflammatory response |
GO_0008283 | Biological process | cell population proliferation |
GO_0030210 | Biological process | heparin biosynthetic process |
GO_0030900 | Biological process | forebrain development |
GO_0060976 | Biological process | coronary vasculature development |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0015015 | Biological process | heparan sulfate proteoglycan biosynthetic process, enzymatic modification |
GO_0045880 | Biological process | positive regulation of smoothened signaling pathway |
GO_0003279 | Biological process | cardiac septum development |
GO_0048703 | Biological process | embryonic viscerocranium morphogenesis |
GO_0048702 | Biological process | embryonic neurocranium morphogenesis |
GO_0030901 | Biological process | midbrain development |
GO_0008543 | Biological process | fibroblast growth factor receptor signaling pathway |
GO_0007585 | Biological process | respiratory gaseous exchange by respiratory system |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0032588 | Cellular component | trans-Golgi network membrane |
GO_0000139 | Cellular component | Golgi membrane |
GO_0102140 | Molecular function | heparan sulfate N-deacetylase activity |
GO_0019213 | Molecular function | deacetylase activity |
GO_0015016 | Molecular function | [heparan sulfate]-glucosamine N-sulfotransferase activity |
GO_0050119 | Molecular function | N-acetylglucosamine deacetylase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | NDST1 |
Protein name | N-deacetylase and N-sulfotransferase 1 Bifunctional heparan sulfate N-deacetylase/N-sulfotransferase 1 (Glucosaminyl N-deacetylase/N-sulfotransferase 1) (NDST-1) (N-heparan sulfate sulfotransferase 1) (N-HSST 1) ([Heparan sulfate]-glucosamine N-sulfotransferase 1) (HSNST 1) [Includes: Heparan sulfate N-deacetylase 1 (EC 3.5.1.-); Heparan sulfate N-sulfotransferase 1 (EC 2.8.2.8)] Alternative protein NDST1 |
Synonyms | HSST1 HSST |
Description | FUNCTION: [Isoform 1]: Essential bifunctional enzyme that catalyzes both the N-deacetylation and the N-sulfation of glucosamine (GlcNAc) of the glycosaminoglycan in heparan sulfate . Modifies the GlcNAc-GlcA disaccharide repeating sugar backbone to make N-sulfated heparosan, a prerequisite substrate for later modifications in heparin biosynthesis . Plays a role in determining the extent and pattern of sulfation of heparan sulfate. Participates in biosynthesis of heparan sulfate that can ultimately serve as L-selectin ligands, thereby playing a role in inflammatory response (By similarity). Required for the exosomal release of SDCBP, CD63 and syndecan . .; FUNCTION: [Isoform 3]: Lacks both N-deacetylase and N-sulfotransferase activities. Acts as a dominant negative on isoform 1, likely by changing the composition of enzyme complexes responsible for elongation and modification of heparan sulfates. . |
Accessions | ENST00000519157.1 E5RGN9 L0R5C1 E5RG58 ENST00000261797.7 [P52848-1] ENST00000523767.5 [P52848-3] ENST00000518299.1 P52848 E5RG24 ENST00000522491.1 |